Mexico

BMI View: The expansion of pharmaceutical companies in emerging markets and their increasing global business integration will boost the shipping volumes of biological and temperature-sensitive... 2013-01-15

BMI View: Mexico's relatively low-cost business environment, growing domestic pharmaceutical market and the improving regulatory regime have made it an attractive market to multinationals.... 2013-01-10

BMI View: Mexico's relatively favourable regulatory environment for foreign drugmakers and its well recognised drug approval standard among Latin American countries should encourage... 2012-11-08

BMI View: Mexico's open economy and its comparably transparent regulatory regime have provided more direct access to its pharmaceutical market for innovative drugmakers and will facilitate... 2012-10-29

BMI View: Mexico's biologics and biosimilar guidelines will encourage more pharmaceutical companies to launch 'biocomparables', and undermine innovative drugmakers' revenue-generating... 2012-09-20

BMI View: The Mexican pharmaceutical market has become an increasingly attractive prospect for Spanish companies. It offers such companies potential revenue-generating opportunities... 2012-09-17

BMI View: GSK Mexico's strategy has identified unmet medical needs in Mexico and will help the company to capitalise on its areas of strength - including treatments for cardiovascular... 2012-09-04